RT @SattuiSEMD: L06: Mavrilimumab in #GCA ⭐️Efficacy and safety of MAV maintaining sustained remission 26w new and r
Tweet Content
L06: Mavrilimumab in #GCA
⭐️Efficacy and safety of MAV maintaining sustained remission 26w new and relapsing/ref #GCA
Flare risk ➡️ 62% risk ⬇️ of flare w/ MAV
Sustained remission➡️ 33% ⬆️ in MAV
No diff in new or relapsing/ref pts,
No diff in AE
#ACR20 #ACRambassador
Show on Archive Page
On
Display in Search Results
On